|Fenofibrate triggers apoptosis of glioblastoma cells in vitro: new insights for therapy.|
|Jump to Full Text|
|PMID: 22895169 Owner: NLM Status: MEDLINE|
|Antonio Giordano; Marcella Macaluso|
Related Documents :
|22819259 - Blockade of nfκb activity by sunitinib increases cell death in bortezomib-treated endo...
12237739 - Adenosine 5'-triphosphate axis in obstructive airway diseases.
17993169 - In search of mitochondrial mechanisms: interfield excursions between cell biology and b...
17882379 - Cytokinesis in development and disease: variations on a common theme.
22530779 - Naphthoquinones from onosma paniculata induce cell-cycle arrest and apoptosis in melano...
12094229 - Organogenesis: molecular mechanisms of tubulogenesis.
7054589 - Structure of alveolar epithelial cells in patients with fibrotic lung disorders.
3245789 - Studies on cell migration, adenylate cyclase and membrane-coating granules in the bucca...
18687359 - Femtosecond laser-assisted microinjection into living neurons.
|Type: Comment; News Date: 2012-08-16|
|Title: Cell cycle (Georgetown, Tex.) Volume: 11 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2012 Sep|
|Created Date: 2012-09-13 Completed Date: 2013-02-04 Revised Date: 2013-07-12|
Medline Journal Info:
|Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States|
|Languages: eng Pagination: 3154 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Apoptosis Regulatory Proteins / metabolism*
Fenofibrate / toxicity*
Forkhead Transcription Factors / metabolism*
Hypolipidemic Agents / toxicity*
Membrane Proteins / metabolism*
Proto-Oncogene Proteins / metabolism*
|0/Apoptosis Regulatory Proteins; 0/Forkhead Transcription Factors; 0/Hypolipidemic Agents; 0/Membrane Proteins; 0/Proto-Oncogene Proteins; 49562-28-9/Fenofibrate|
|Cell Cycle. 2012 Jul 15;11(14):2660-71
Journal ID (nlm-ta): Cell Cycle
Journal ID (iso-abbrev): Cell Cycle
Journal ID (publisher-id): CC
Publisher: Landes Bioscience
Copyright © 2012 Landes Bioscience
Print publication date: Day: 01 Month: 9 Year: 2012
pmc-release publication date: Day: 01 Month: 9 Year: 2012
Volume: 11 Issue: 17
First Page: 3154 Last Page: 3154
PubMed Id: 22895169
Publisher Id: 2012NV0739
Publisher Item Identifier: 21719
|Fenofibrate triggers apoptosis of glioblastoma cells in vitro : New insights for therapy|
1Sbarro Institute for Cancer Research and Molecular Medicine; Center for Biotechnology; College of Science and Technology; Temple University; Philadelphia, PA USA
2Department of Human Pathology and Oncology; University of Siena; Siena, Italy
|*Correspondence to: Marcella Macaluso, Email: firstname.lastname@example.org
Fenofibrate, a peroxisome proliferator-activated receptor (PPARα) agonist, is a member of the fibrate class of anti-hyperlipidemic agents and has been widely used in the treatment of different forms of hyperlipidemia and hypercholesterolemia.1 PPARa is a ligand-inducible transcription factor that belongs to the nuclear-hormone-receptor family and mediates peroxisome proliferation action. Interestingly, growing evidence has indicated that PPARa agonist fenofibrate exerts anticancer properties, probably because of its anti-proliferative and pro-apoptotic activities, and, importantly, exhibits low systemic toxicity.2 However, it is not clear what role PPARa plays in the antiproliferative effect of fenofibrate, and the possibility of a PPARa-independent action is being considered. With respect to these mechanisms, in a recent issue of Cell Cycle, Wilk, et al.3 investigated the effect of fenofibrate treatment on the proliferative features of glioblastoma cells. Approximately, 50% of all primary brain tumors originate from glial cells, and glioblastoma multiforme (GBM) is by far the most common and most malignant of the glial tumors. Currently, the treatment of glioblastomas remains palliative and includes surgery, radiotherapy, chemotherapy and treatment with inhibitors and antibodies, which have been shown to prolong quality survival.4
In their study, Wilk, et al.3 show that fenofibrate can effectively induce growth arrest and trigger apoptosis of glial tumor cells in a dose- and time-dependent manner. Interestingly, the authors observed that fenofibrate-induced apoptosis was preceded by nuclear accumulation and serine phosphorylation of the transcription factor FoxO3A as well as by FoxO-dependent expression of the pro-apoptotic protein Bim. In addition, the authors observed that other agonists of PPARa were less effective in changing cell viability with respect to fenofibrate, and that PPARα silencing by siRNA only partially rescued glioblastoma cells from the treatment, suggesting that both PPARa-dependent and -independent mechanisms may play a role in the fenofibrate-induced activation of FoxO3A and Bim, which, in turn, triggers apoptosis.
Different studies have reported that deregulation of the p16Ink4a-Cdk4-Rb cell cycle-controlling pathway is a common event in patients with GBM.5,6 It would be very interesting to investigate the impact of fenofibrate treatment on p16-Cdk4/6-Rb axis and its relationship with apoptosis triggering and cytotoxicity effects in glioblastoma cells. Not all glioblastomas have the same biological abnormalities, and this may be the reason why different patients respond differently to the same treatment, and why different patients with the same tumor type have different outcomes. In this context, it would be interesting to disclose the pleiotropic effects of fenofibrate on cell growth and death signaling and to determine if the response to this drug could be critically determined by p16Ink4a-Cdk4-Rb status in glioblastoma cells. Wilk, et al.’s study provides evidence that fenofibrate treatment can effectively trigger apoptosis via FoxO3A in glioblastoma cells, and this information may represent the first step in elucidating the anticancer effect(s) of this drug. Further studies are necessary to evaluate the impact of fenofibrate treatment in modulating cellular growth and death signaling of glioblastoma cells and to shed light on how the use of this drug may improve current anticancer therapies.
Previously published online: www.landesbioscience.com/journals/cc/article/21719
|1.||van der Hoogt CC,et al. J Lipid ResYear: 20074817637110.1194/jlr.M700108-JLR20017525476|
|2.||Drukala J,et al. Mol CancerYear: 2010915910.1186/1476-4598-9-15920569465|
|3.||Wilk A,et al. Cell CycleYear: 20121126607110.4161/cc.2101522732497|
|4.||Lima FR,et al. Biochim Biophys ActaYear: 201218263384922677165|
|5.||Ueki K,et al. Cancer ResYear: 19965615038548755|
|6.||Parsons DW,et al. ScienceYear: 200832118071210.1126/science.116438218772396|
Keywords: Keywords: FoxO3A, PPARα, anticancer properties, fenobribate, glioblastoma.
Previous Document: Selection of key ambient particulate variables for epidemiological studies - Applying cluster and he...
Next Document: Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death recept...